Patient P-02001
Synthetic patientMETA-24 · Day 179 · 65–74 · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Improving
GI state
Favorable
Inflammatory state
Favorable
Nutritional resilience
Favorable
Discontinuation risk
16%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- GI instability-4
- Toxicity-4
- Inflammatory activity-3
- Nutritional resilience+3
- Treatment adherence+3
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable26 min
worsening · -4.1 vs previous 14 d
Sleep duration
Wearable5.8 h
worsening · -0.3 vs previous 14 d
Energy level
Daily log7.2/10
worsening · -0.4 vs previous 14 d
Steps
Wearable3,837
worsening · -351 vs previous 14 d
GI burden
Companion13.2/100
worsening · +7.2 vs previous 14 d
Adherence
Companion97.4 %
stable · -1.2 vs previous 14 d
Sleep quality
Wearable29.8/100
worsening · -6.9 vs previous 14 d
Glucose, CGM daily mean
CGM129 mg/dL
worsening · +5.4 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 96 from the failing basin, 10 from restoration.
Good elements to keep
- Butyrate producers intacthidden · steering +7.5
- Protein (supports)perturbation · steering +7.4
- Proteinsupporter · GI -4.2 next day
Main detractors to watch
- Bacteroides fragilis elevatedhidden · steering -7.4
- Low-HRV stretchperturbation · steering -2.7
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-4.2supporter · 95%
- Insoluble fibre+1.9no signal · 41%
- Simple carbohydrates+1.6no signal · 33%
- Alcohol-0.9no signal · 23%
- Dietary fat load-0.7no signal · 17%
- Histamine load+0.6no signal · 20%
- Caffeine+0.5no signal · 15%
- Ultra-processed food0no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Autonomic recovery ↓40
- Wearable3,837 steps/day
- WearableShort sleep window
- Inflammatory signalling ↓35
- MicrobiomeBacteroides fragilis expansion
- WearableHRV 36 ms, trending down
- Mucosal barrier integrity ↓10
- WearableSleep 5.8 h, below personal baseline
DNA
Fictional pharmacogenomic panel
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 4.1 · butyrate capacity 51/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 37 ms
- Sleep
- 5.6 h
- Steps
- 4,542
- Resting HR
- 59 bpm
Daily log: GI score 13, nutritional resilience 71, adherence 97.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02337 | 34% | S18 | DT-01 | no change | 100 |
| P-02249 | 39% | S09 | DT-01 | improved | 100 |
| P-02189 | 39% | S17 | — | — | 96 |
| P-02640 | 37% | S03 | — | — | 96 |
| P-02242 | 36% | S20 | — | — | 95 |
| P-02013 | 48% | S14 | BR-03 | no change | 94 |
| P-02104 | 45% | S15 | — | — | 94 |
| P-02450 | 43% | S12 | NP-02 | improved | 92 |
| P-02277 | 43% | S05 | AD-05 | improved | 92 |
| P-02304 | 43% | S15 | — | — | 92 |
| P-02653 | 34% | S14 | — | — | 91 |
| P-02689 | 33% | S13 | — | — | 91 |